Prevention of venous thromboembolic events (VTE): elective hip or knee replacement surgery: Prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery.
Prevention of stroke and systemic embolism: non-valvular atrial fibrillation: APIXA CCP is indicated to reduce the risk of stroke, systemic embolism, and death in patients with non-valvular atrial fibrillation with one or more risk factors, including patients unsuitable for warfarin.
Treatment of venous thromboembolic events (VTE): APIXA CCP is indicated for: treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE).
Other Services
Country
Account